Skip to main content
. 2015 Jul 10;10(7):e0132604. doi: 10.1371/journal.pone.0132604

Fig 8. LDDN-0003499 treatment attenuated Aβ-dependent microglial TNF-α and IL-6 secretion.

Fig 8

Microglial BV2 cells were pretreated for 1 hour with DMSO vehicle (v) or varying concentrations of LDDN-0003499 then stimulated with (A, B, C) 50nM Aβ 1–42 or (E) 25ng/ml LPS in the maintained presence/absence of LDDN-0003499. Media were collected from the cells following 24h stimulation and used to quantify changes in TNF-α (A, E), IL-6 (B) or IL-1β (C) secretion via ELISA. Secreted values from three independent experiments were averaged ± SD (*p< 0.05 respective control vs Aβ, $p<0.05 vs. Aβ only). (D) Media from treated cells were also used assess cell viability via the LDH release assay. Absorbance values were averaged ±SD.